Aliases & Classifications for Intermittent Claudication

MalaCards integrated aliases for Intermittent Claudication:

Name: Intermittent Claudication 37 12 51 41 14 69
Amyotrophic Lateral Sclerosis 69
Intermittent Claudication Nos 12
Charcot's Syndrome 12
Charcot Disease 72

Classifications:



External Ids:

Disease Ontology 12 DOID:3669
ICD10 32 I73.9
MeSH 41 D007383
UMLS 69 C0021775

Summaries for Intermittent Claudication

MalaCards based summary : Intermittent Claudication, also known as amyotrophic lateral sclerosis, is related to critical limb ischemia and peripheral artery disease, and has symptoms including medically unexplained symptoms, hypertriglyceridemic waist and prodromal symptoms. An important gene associated with Intermittent Claudication is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs Angiotensin II and Olmesartan have been mentioned in the context of this disorder. Affiliated tissues include Placenta, endothelial and bone, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 72 Charcot–Marie–Tooth disease (CMT) is one of the hereditary motor and sensory neuropathies, a group of... more...

Related Diseases for Intermittent Claudication

Diseases related to Intermittent Claudication via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 281)
# Related Disease Score Top Affiliating Genes
1 critical limb ischemia 32.3 IL6 VEGFA
2 peripheral artery disease 31.5 ACE CRP IL6 SELP VEGFA
3 carotid stenosis 30.1 ACE CRP SELP
4 limb ischemia 30.0 ACE IL6 VEGFA VWF
5 aortic aneurysm, familial abdominal, 1 29.7 ACE CRP IL6
6 arteriovenous fistula 29.5 APOH IL6
7 systolic heart failure 29.5 ACE CRP IL6
8 polyarteritis nodosa 29.3 APOH CRP IL6
9 arteriosclerosis 29.2 ACE CRP IL6 SELP SERPINE1
10 diabetes mellitus 29.1 ACE ALB CRP IL6 VEGFA
11 coronary artery anomaly 28.9 ACE CRP IL6 SELP SERPINE1
12 angina pectoris 28.7 ACE CRP IL6 SERPINC1 SERPINE1 VWF
13 thrombosis 28.6 APOH F2 SELP SERPINC1 SERPINE1 VWF
14 vascular disease 28.4 ACE APOH CRP SELP SERPINC1 SERPINE1
15 arteries, anomalies of 27.3 ACE ALB CRP F2 IL6 SELP
16 peripheral vascular disease 26.9 ACE ALB CRP F2 IL6 SELP
17 myocardial infarction 26.4 ACE ALB CRP F2 IL6 SELP
18 amyotrophic lateral sclerosis 1 11.0
19 juvenile amyotrophic lateral sclerosis 10.9
20 infiltrating angiolipoma 10.5 VEGFA VWF
21 hypertensive retinopathy 10.5 ACE VWF
22 fibrinolytic defect 10.4 SERPINC1 SERPINE1
23 heparin-induced thrombocytopenia 10.4 SELP SERPINC1
24 argentine hemorrhagic fever 10.4 SERPINC1 SERPINE1
25 sticky platelet syndrome 10.4 SERPINC1 SERPINE1
26 malignant otitis externa 10.4 CRP F2
27 renal artery obstruction 10.4 ACE SERPINC1
28 episodic pain syndrome, familial, 1 10.4
29 angiodysplasia 10.4 VEGFA VWF
30 pyuria 10.3 ALB CRP
31 von willebrand disease, type 1 10.3 F2 VWF
32 japanese spotted fever 10.3 CRP SERPINC1
33 generalized atherosclerosis 10.3 ACE CRP SELP
34 endotheliitis 10.3
35 active peptic ulcer disease 10.3 F2 VWF
36 platelet aggregation, spontaneous 10.3 SELP SERPINC1 VWF
37 ischemia 10.3
38 aortic valve disease 1 10.3 ACE CRP VWF
39 orthostatic proteinuria 10.3 ACE ALB
40 ischemic neuropathy 10.3 CRP F2
41 hepatoportal sclerosis 10.3 ACE F2
42 coronary thrombosis 10.3 SERPINC1 SERPINE1 VWF
43 acroosteolysis 10.3 ALB VEGFA
44 aortic valve disease 2 10.3 ACE CRP VWF
45 legg-calve-perthes disease 10.3 SELP SERPINC1 SERPINE1
46 coronary restenosis 10.3 ACE SERPINC1
47 spinal stenosis 10.3
48 systemic scleroderma 10.3 ACE CRP SELP
49 coronary heart disease 1 10.3 ACE CRP SERPINE1
50 decubitus ulcer 10.3 ALB CRP

Comorbidity relations with Intermittent Claudication via Phenotypic Disease Network (PDN):


Acute Cystitis Motor Neuron Disease
Primary Lateral Sclerosis, Adult, 1 Protein-Energy Malnutrition
Respiratory Failure Swallowing Disorders

Graphical network of the top 20 diseases related to Intermittent Claudication:



Diseases related to Intermittent Claudication

Symptoms & Phenotypes for Intermittent Claudication

UMLS symptoms related to Intermittent Claudication:


medically unexplained symptoms, hypertriglyceridemic waist, prodromal symptoms, mobility limitation, urological manifestations, hot flushes, renal colic, polydipsia, chills, skin manifestations, signs and symptoms, respiratory, signs and symptoms, digestive, signs and symptoms, oral manifestations, fatigue, eye manifestations, edema, cyanosis, body temperature changes, asthenia, sleeplessness, vertigo/dizziness, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, back pain

MGI Mouse Phenotypes related to Intermittent Claudication:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 VWF ACE SELP SERPINC1 SERPINE1 CRP
2 homeostasis/metabolism MP:0005376 10.1 VWF ACE SELP ALB SERPINC1 APOH
3 immune system MP:0005387 9.91 VWF VEGFA IL6 ACE SELP SERPINC1
4 digestive/alimentary MP:0005381 9.85 VWF VEGFA IL6 ALB F2 HTR2A
5 liver/biliary system MP:0005370 9.7 ACE SELP ALB SERPINC1 SERPINE1 VEGFA
6 mortality/aging MP:0010768 9.7 VWF ACE SELP ALB SERPINC1 APOH
7 renal/urinary system MP:0005367 9.17 VEGFA IL6 ACE SELP ALB SERPINC1

Drugs & Therapeutics for Intermittent Claudication

Drugs for Intermittent Claudication (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
2
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
3
Paclitaxel Approved, Vet_approved Phase 4,Phase 3 33069-62-4 36314
4
Cilostazol Approved, Investigational Phase 4,Phase 2,Phase 1 73963-72-1 2754
5
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
6
Metformin Approved Phase 4 657-24-9 4091 14219
7
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-78-2 2244
8
Clopidogrel Approved Phase 4,Phase 2 120202-66-6, 113665-84-2 60606
9
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 46507594 772
10
Ramipril Approved Phase 4 87333-19-5 5362129
11
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
12
Allopurinol Approved Phase 4 315-30-0 2094
13
Alprostadil Approved, Investigational Phase 4,Phase 3,Phase 2 745-65-3 149351
14
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
15
Pentoxifylline Approved, Investigational Phase 4,Phase 3 6493-05-6 4740
16
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 3 111025-46-8 4829
17
Ticagrelor Approved Phase 4 274693-27-5 9871419
18
Thrombin Approved, Investigational Phase 4
19
Vorapaxar Approved Phase 4 618385-01-6
20
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
21
Losartan Approved Phase 4 114798-26-4 3961
22
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
23
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
24
Gliclazide Approved Phase 4 21187-98-4 3475
25
Glimepiride Approved Phase 4 93479-97-1 3476
26
Glyburide Approved Phase 4 10238-21-8 3488
27 tannic acid Approved, Nutraceutical Phase 4
28
Candesartan Experimental Phase 4 139481-59-7 2541
29
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
30 Adrenergic alpha-Antagonists Phase 4
31 Adrenergic beta-Antagonists Phase 4
32 Angiotensin II Type 1 Receptor Blockers Phase 4
33 Angiotensin Receptor Antagonists Phase 4
34 Angiotensinogen Phase 4
35 Antihypertensive Agents Phase 4,Phase 1,Phase 2
36 diuretics Phase 4
37
Olmesartan medoxomil Phase 4 144689-63-4 130881
38 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Albumin-Bound Paclitaxel Phase 4,Phase 3
40 Antimitotic Agents Phase 4,Phase 3
41 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2
42 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2
43 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 1
44 Autonomic Agents Phase 4,Phase 2,Phase 1
45 Bronchodilator Agents Phase 4,Phase 2,Phase 1
46 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Neuroprotective Agents Phase 4,Phase 2,Phase 1
48 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
49 Phosphodiesterase 3 Inhibitors Phase 4,Phase 2,Phase 1
50 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 181)

# Name Status NCT ID Phase Drugs
1 Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF) Unknown status NCT02373462 Phase 4 Olmesartan;other anti-hypertensive drug
2 ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion Unknown status NCT00407940 Phase 4
3 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis Unknown status NCT02033135 Phase 4
4 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4 cilostazol;Placebo
5 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Unknown status NCT01901224 Phase 4 Metformin 1000 mg;Placebo
6 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
7 Self Expanding Nitinol Stent Versus Percutaneous Transluminal Arterial Angioplasty (PTA) With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication (EXPAND) Completed NCT00906022 Phase 4
8 Evaluation of Cilostazol in Combination With L-Carnitine Completed NCT00822172 Phase 4 cilostazol
9 Neurogenic Intermittent Claudication Evaluation Study Completed NCT00905359 Phase 4
10 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4 Aspirin
11 Intermittent Neurogenic Claudication Treatment With APERIUS® Completed NCT00887744 Phase 4
12 Angioplasty in Peripheral Arterial Disease and Endothelial Function Completed NCT00660634 Phase 4
13 PTA vs. Primary Stenting of SFA Using Self-Expandable Nitinol Stents Completed NCT00715416 Phase 4
14 Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft (PopUp) Completed NCT00300690 Phase 4
15 Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants Completed NCT01037530 Phase 4 Ramipril
16 DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
17 Efficacy Study of Iliac Stents to Treat TASC A-B-C-D Iliac Artery Lesions Completed NCT00764777 Phase 4
18 Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease Completed NCT01147705 Phase 4 Allopurinol;Placebo
19 The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease Completed NCT00168467 Phase 4 Ramipril
20 A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis Completed NCT01888536 Phase 4 Limaprost;Pregabalin;Placebo(for Pregabalin);Placebo(for Limaprost)
21 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study Completed NCT00228384 Phase 4
22 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Recruiting NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
23 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Recruiting NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
24 Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial Active, not recruiting NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
25 The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication Terminated NCT01799057 Phase 4 Metformin;Placebo
26 Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant Terminated NCT01057641 Phase 4
27 Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Terminated NCT00437905 Phase 4
28 Condition of Approval Study Terminated NCT00517751 Phase 4
29 Effects of X-STOP® Versus Laminectomy Study Withdrawn NCT00558129 Phase 4
30 Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients Withdrawn NCT02121288 Phase 4 Ticagrelor;clopidogrel
31 PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients Unknown status NCT00251849 Phase 3 Rifalazil
32 Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia Unknown status NCT00539266 Phase 2, Phase 3
33 Caffeine and Intermittent Claudication Completed NCT00388128 Phase 3 Caffeine 6mg/kg
34 Prostaglandin E1 in Outpatients With Intermittent Claudication Completed NCT01263925 Phase 3 Alprostadil (Prostaglandin E1);Pentoxifylline;Placebo to Pentoxifylline oral;Placebo to Alprostadil (Prostaglandin E1) intravenous
35 Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication Completed NCT00062556 Phase 3 Niacin Extended Release and Lovastatin Tablets
36 The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC Completed NCT00071266 Phase 3 Niacin Extended Release and Lovastatin Tablets
37 Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication) Completed NCT00399919 Phase 3 Propionyl-L-Carnitine;PLC
38 ARREST PAD (Peripheral Arterial Disease) Completed NCT00153166 Phase 2, Phase 3 atorvastatin and pioglitazone;atorvastatin/placebo;pioglitazone/placebo;placebo/placebo
39 Strength Training in Walking Tolerance in Intermittent Claudication Patients Completed NCT00879697 Phase 3
40 Evaluating Two Exercise Training Programs to Reduce Leg Pain in People With Peripheral Arterial Disease (The EXERT Study) Completed NCT00895635 Phase 3
41 Dacron vs Dardik for Fem-Pop Bypass Completed NCT00523263 Phase 3
42 Does the Reduction of Total Body Iron Storage (TBIS) Alter Mortality in a Population of Patients With Advanced PVD? Completed NCT00032357 Phase 3
43 Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries Completed NCT00352222 Phase 3
44 A Clinical Study on Efficacy & Safety Profile of Propionyl-L-carnitine Tablets for Peripheral Arterial Diseases Completed NCT00809497 Phase 3 Propionyl-L-carnitine Tablets
45 Intensive Rehabilitation in Peripheral Arterial Disease With Claudication: Effects of a Treadmill Training With Active Recovery Completed NCT01734603 Phase 3
46 Paclitaxel Eluting Stent in Long SFA Obstruction: A Prospective, Randomized Comparison With Bypass Surgery Recruiting NCT01450722 Phase 3
47 Efficacy of Sildenafil on the Morbi-mortality of Peripheral Arterial Diseased Patients With Intermittent Claudication Not yet recruiting NCT02930811 Phase 3 Sildenafil 100 mg oral morning dose;Placebo oral morning dose
48 Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral Artery Disease TENS-PAD Study / TENS-AOMI Not yet recruiting NCT02678403 Phase 3
49 The Effects of Fish Oil Supplements During Supervised Exercise Therapy in Patients With Intermittent Claudication Terminated NCT02152930 Phase 3 Omega-3 fatty acids
50 SIMPADICO - Study of Immune Modulation Therapy in Peripheral Arterial Disease and Intermittent Claudication Outcomes Terminated NCT00111826 Phase 3

Search NIH Clinical Center for Intermittent Claudication

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intermittent Claudication cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: intermittent claudication

Genetic Tests for Intermittent Claudication

Anatomical Context for Intermittent Claudication

MalaCards organs/tissues related to Intermittent Claudication:

38
Endothelial, Bone, Testes, Skeletal Muscle, Smooth Muscle, Heart, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Intermittent Claudication:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate

Publications for Intermittent Claudication

Articles related to Intermittent Claudication:

(show top 50) (show all 656)
# Title Authors Year
1
Combination of endovascular revascularization and supervised exercise therapy for intermittent claudication: a systematic review and meta-analysis. ( 29327569 )
2018
2
Exploring physical activity behaviour - needs for and interest in a technology-delivered, home-based exercise programme among patients with intermittent claudication. ( 29144207 )
2018
3
Achilles tendon elasticity decreases with intermittent claudication in patients by Acoustic Radiation Force Impulse Imaging (ARFI). ( 29371711 )
2018
4
Systematic review and meta-analysis of high-pressure intermittent limb compression for the treatment of intermittent claudication. ( 29389425 )
2018
5
Use of Telehealth as a New Model for Following Intermittent Claudication and Promoting Patient Expertise. ( 29323628 )
2018
6
Cardiovascular and all-cause mortality in patients with intermittent claudication and critical limb ischaemia. ( 29116654 )
2018
7
A Rare Case of Intermittent Claudication Associated with Impaired Arterial Vasodilation. ( 29435381 )
2017
8
Identifying content gaps in health status measures for intermittent claudication using the International Classification of Functioning, Disability and Health. ( 29074112 )
2017
9
The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication: study protocol for a randomised controlled trial: the TENS-PAD study. ( 28797281 )
2017
10
Centers for Medicare and Medicaid Services Policy Regarding Supervised Exercise for Patients With Intermittent Claudication: The Good, the Bad, and the Ugly. ( 29191119 )
2017
11
Intermittent Claudication ( 28613529 )
2017
12
Improved Adherence to a Stepped-care Model Reduces Costs of Intermittent Claudication Treatment in The Netherlands. ( 28539212 )
2017
13
"Intermittent claudication a real pain in the calf"-Patient experience of diagnosis and treatment with a supervised exercise program. ( 28838587 )
2017
14
A Case of Polyarteritis Nodosa Presenting as Rapidly Progressing Intermittent Claudication of Right Leg. ( 29109739 )
2017
15
Functional electrical stimulation improves quality of life by reducing intermittent claudication. ( 28595744 )
2017
16
Reproducibility of heart rate recovery in patients with intermittent claudication. ( 28752607 )
2017
17
Exercise training for intermittent claudication. ( 28874320 )
2017
18
Unloading shoes for intermittent claudication: a randomised crossover trial. ( 29179693 )
2017
19
A feasibility double-blind randomized placebo-controlled trial of extracorporeal shockwave therapy as a novel treatment for intermittent claudication. ( 28943002 )
2017
20
The Effect of Structured Patient Education on Physical Activity in Patients with Peripheral Arterial Disease and Intermittent Claudication: A Systematic Review. ( 28528678 )
2017
21
A systematic review of muscle morphology and function in intermittent claudication. ( 28822657 )
2017
22
Amputation Rates, Mortality, and Pre-operative Comorbidities in Patients Revascularised for Intermittent Claudication or Critical Limb Ischaemia: A Population Based Study. ( 28797662 )
2017
23
Choosing the individual rehabilitation program for patients with intermittent claudication. ( 28691674 )
2017
24
Long-term results with percutaneous interspinous process devices in the treatment of neurogenic intermittent claudication. ( 29354740 )
2017
25
Quality of life in patients with intermittent claudication. ( 28529410 )
2017
26
Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease. ( 27763685 )
2017
27
Long-term survival and fate of the leg in de novo intermittent claudication. ( 28838085 )
2017
28
Intermittent claudication and severe renal artery stenosis are independently associated in hypertensive patients referred for renal arteriography. ( 28793000 )
2017
29
Intravenous alprostadil treatment compared to oral pentoxifylline treatment in outpatients with intermittent claudication - results of a randomised clinical trial. ( 28558485 )
2017
30
Patients With Intermittent Claudication and Chronic Widespread Pain Improves in Health-Related Quality of Life After Invasive but Not After Noninvasive Treatment. ( 29308018 )
2017
31
User Preferences for Mobile Health Interventions: A Survey Among Intermittent Claudication Patients and Their Physical Therapists. ( 28893710 )
2017
32
Baseline assessment and comparison of arterial anatomy, hyperemic flow, and skeletal muscle perfusion in peripheral artery disease: The Cardiovascular Cell Therapy Research Network "Patients with Intermittent Claudication Injected with ALDH Bright Cells" (CCTRN PACE) study. ( 27979038 )
2017
33
Two otherwise healthy young brothers present with intermittent claudication, just a coincidence? ( 28684644 )
2017
34
Supervised Exercise Therapy for Intermittent Claudication Is Increasingly Endorsed by Dutch Vascular Surgeons. ( 28893711 )
2017
35
Exercise for intermittent claudication. ( 29278423 )
2017
36
Two-year results from a randomized clinical trial of revascularization in patients with intermittent claudication. ( 27220310 )
2016
37
Additional functional outcomes after endovascular treatment for intermittent claudication. ( 27872352 )
2016
38
Altered joint kinematics and increased electromyographic muscle activity during walkingA in patients with intermittent claudication. ( 26781076 )
2016
39
A systematic review of the uptake and adherence rates to supervised exercise programmes in patients with intermittent claudication. ( 27126713 )
2016
40
Self-administered versus interview-based questionnaires among patients with intermittent claudication: Do they give different results? A cross-sectional study. ( 26786606 )
2016
41
Patterns and determinants of use of pharmacological therapies for intermittent claudication in outpatients with peripheral artery disease. Results of the IDOMENEO study. ( 27598470 )
2016
42
Interspinous process devices for the treatment of neurogenic intermittent claudication: a systematic review of randomized controlled trials. ( 27178046 )
2016
43
Patient education interventions to improve physical activity in patients with intermittent claudication: a protocol for a systematic mixed-studies review. ( 27207628 )
2016
44
Determining the Minimally Important Difference for the VascuQol Sumscore and Its Domains in Patients with Intermittent Claudication. ( 26837479 )
2016
45
Review of research article: Comparison ofA two treadmill training programs on walking ability and endothelial function inA intermittent claudication by Mika P, Konik A, Januszek T, Nowobilski R, Nizankowski R, Szczeklik A (Int J CardiolA 2013; 168: 838-842). ( 27568319 )
2016
46
TCT-788 Safety and Efficacy of Endovascular Therapy for Octogenarians with Peripheral Artery Disease presenting Intermittent Claudication due to Aortoiliac Lesions. ( 27970174 )
2016
47
A Systematic Review of Extracorporeal Shockwave Therapy as a Novel Treatment for Intermittent Claudication. ( 27311948 )
2016
48
Capillary ultrastructure and mitochondrial volume density in skeletal muscle in relation to reduced exercise capacity of patients with intermittent claudication. ( 27009051 )
2016
49
Comparison of use of Short Form-36 domain scores and patient responses for derivation of preference-based SF6D index to calculate quality adjusted life years (QALYs) in patients with intermittent claudication. ( 27177712 )
2016
50
Minimally Important Difference of the Absolute and Functional Claudication Distance in Patients with Intermittent Claudication. ( 26715076 )
2016

Variations for Intermittent Claudication

Copy number variations for Intermittent Claudication from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 107025 17 11200000 22100000 Microduplication Charcot

Expression for Intermittent Claudication

Search GEO for disease gene expression data for Intermittent Claudication.

Pathways for Intermittent Claudication

GO Terms for Intermittent Claudication

Cellular components related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.92 ACE ALB APOH CRP F2 SERPINC1
2 extracellular region GO:0005576 9.65 ACE ALB APOH CRP F2 IL6
3 endoplasmic reticulum lumen GO:0005788 9.56 ALB F2 IL6 SERPINC1
4 platelet alpha granule lumen GO:0031093 9.46 ALB SERPINE1 VEGFA VWF
5 extracellular space GO:0005615 9.32 ACE ALB APOH CRP F2 IL6

Biological processes related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.88 F2 IL6 SERPINE1 VEGFA
2 cellular protein metabolic process GO:0044267 9.78 ALB F2 IL6 SERPINC1
3 platelet activation GO:0030168 9.74 F2 IL6 VWF
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.7 HTR2A IL6 VEGFA
5 defense response to Gram-negative bacterium GO:0050829 9.69 IL6 SELP SERPINE1
6 hemostasis GO:0007599 9.63 F2 SERPINC1 VWF
7 fibrinolysis GO:0042730 9.58 F2 SERPINE1
8 negative regulation of blood coagulation GO:0030195 9.56 APOH SERPINE1
9 positive regulation of leukocyte migration GO:0002687 9.55 SELP VEGFA
10 neutrophil mediated immunity GO:0002446 9.54 ACE IL6
11 acute-phase response GO:0006953 9.54 CRP F2 IL6
12 regulation of blood coagulation GO:0030193 9.5 APOH F2 SERPINC1
13 negative regulation of lipid storage GO:0010888 9.49 CRP IL6
14 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.43 ACE VEGFA
15 blood coagulation, intrinsic pathway GO:0007597 9.43 APOH F2 VWF
16 positive regulation of STAT protein import into nucleus GO:2000366 9.4 F2 IL6
17 positive regulation of blood coagulation GO:0030194 9.33 APOH F2 SERPINE1
18 negative regulation of fibrinolysis GO:0051918 9.13 APOH F2 SERPINE1
19 platelet degranulation GO:0002576 9.1 ALB APOH SELP SERPINE1 VEGFA VWF

Molecular functions related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 ALB APOH CRP SERPINC1 VEGFA VWF
2 protease binding GO:0002020 9.43 SERPINC1 SERPINE1 VWF
3 drug binding GO:0008144 9.13 ACE ALB HTR2A
4 heparin binding GO:0008201 9.02 APOH F2 SELP SERPINC1 VEGFA

Sources for Intermittent Claudication

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....